Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

SIMPLE SUMMARY: This study aimed to evaluate the correlation between adverse events (AEs) and overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo/beva). Liver injuries were significantly correlated with shorter survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimose, Shigeo, Iwamoto, Hideki, Tanaka, Masatoshi, Niizeki, Takashi, Kajiwara, Masahiko, Itano, Satoshi, Moriyama, Etsuko, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Nakano, Masahito, Kuromatsu, Ryoko, Koga, Hironori, Kawaguchi, Takumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454839/
https://www.ncbi.nlm.nih.gov/pubmed/36077816
http://dx.doi.org/10.3390/cancers14174284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454839/
https://www.ncbi.nlm.nih.gov/pubmed/36077816
http://dx.doi.org/10.3390/cancers14174284

Ejemplares similares